Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines Leukemia (2010) Peripheral T-cell lymphomas (PTCLs) are among the most aggressive of all lymphomas and are associated with a poor prognosis compared with aggressive B-cell lymphomas. Therefore, novel targeted therapies are needed. Syk is a protein tyrosine kinase involved in B-cell receptor signaling in both normal and malignant B cells. 1 Syk activation in B-cell lymphomas is associated with cell growth and survival, and an (a) Domain organization of the three BCR-ABL variants tested in this study. The coiled-coil (CC), DBL and pleckstrin homology (PH) domains pertain to BCR; the SH3, SH2 and TK domains pertain to ABL. The p200 BCR-ABL variant lacks the PH domain, while p190 BCR-ABL lacks both the PH and DBL-like domains. Each BCR-ABL variant was stably expressed in 32D cells and whole-cell lysates were subjected to immunoblot analysis with antibodies specific for (b) ABL or (c) global tyrosine phosphorylation (4G10). (d) Immunoblot analysis of STAT5 and STAT6 phosphorylation in whole cell lysates from Ba/F3 cells expressing each of the three BCR-ABL variants. (e-h) Deletion of the PH domain is sufficient to increase the lymphoid transformation potency of BCR-ABL. Donor bone marrow cells from (e) 5-FU-treated Balb/c mice or (f) non-5-FU-treated Balb/c mice were infected with equivalent titer retrovirus expressing p210 BCR-ABL , p200
BCR-ABL or p190 BCR-ABL and transplanted into lethally irradiated recipient mice. Kaplan-Meier survival curves are shown. Mortality events due to CML-like disease, B-ALL-like disease and unrelated causes are marked with square, circle and triangle symbols, respectively. (g, h) Representative fluorescence-activated cell sorting analyzes for CML-like and B-ALL-like disease, respectively. Peripheral blood cells were measured for GFP expression on the y axis. The x axis represents staining with antibodies specific for myeloid cells (Ly6G), B cells (B220), T cells (Thy1.2), early myeloid cells (CD11b) or erythroid cells (Ter119). CML-like and B-ALL-like disease was analyzed in different mouse tissues using GFP (y axis) and either Ly6G or B220 (x axis), respectively. orally available Syk inhibitor is currently being tested for B-cell lymphomas in a phase I/II clinical trial, with encouraging results. 2 Normal T lymphocytes lack Syk expression and use a Syk homolog, Zap-70, in receptor signaling. However, we recently showed that Syk protein is aberrantly expressed in the majority of PTCLs. 3 The functional role of Syk in PTCL is currently unknown. Herein, we show that silencing Syk induces apoptosis and blocks proliferation in PTCL cells. These findings suggest that Syk represents a novel therapeutic target for patients with PTCL.
To establish an in vitro model for examining the effects of Syk inhibition, we analyzed Syk expression in multiple PTCL cell lines (SeAx, HuT 78, SR-786, Karpas 299 and SU-DHL-1) by both western blot ( Figure 1a ) and flow cytometry (Figure 1b) . Consistent with our previously reported data showing Syk expression in PTCL, three of five cell lines tested (SU-DHL-1, SR-786 and SeAx) showed strong Syk expression. 3 Next, we determined the phosphorylation status of Syk in these cell lines. SU-DHL-1 and SR-786 cells, but not SeAx cells, showed Syk phosphorylation at Y348 (Figure 1c and d) , a site autophosphorylated on B-cell receptor engagement in B cells. 4 Syk was also phosphorylated at Y525/526 in both SU-DHL-1 and SR-786 (data not shown).
To determine whether Syk contributes to the growth and survival of T-cell lymphomas, a small interfering RNA (siRNA) approach was used to inhibit Syk expression. Syk siRNA effectively silenced Syk expression in both SU-DHL-1 and SR-786 cells ( Figure 2a ). As Syk inhibition blocks proliferation and induces apoptosis in B-cell lymphomas, 1 we determined the effects of Syk siRNA on PTCL cells. In both SU-DHL-1 and SR-786, Syk siRNA significantly reduced both proliferation ( 3 H-TdR incorporation, Figure 2b ) and cell viability (annexin V assay, Figure 2c ). Syk siRNA also silenced Syk expression in SeAx cells, in which Syk is not phosphorylated (data not shown). Proliferation of SeAx cells was determined after treatment with either a control or Syk siRNA in a manner identical to that described in Figure 2b . No significant difference in proliferation (67 691 þ /À 1974 cpm versus 73 884 þ /À 3467 cpm, respectively; n ¼ 3) was observed between the two treatment groups.
As siRNA-based inhibition of therapeutic targets is difficult to achieve clinically, we determined whether a Syk inhibitor currently in clinical trial, R406, 2 would recapitulate the functional effects of Syk siRNA in PTCL cells. As expected, R406 led to dephosphorylation of Syk in both SU-DHL-1 and SR-786 (Figure 2d ). Furthermore, R406 significantly inhibited cell proliferation in a dose-dependent manner (Figure 2e ), and induced cell death in The events leading to Syk activity in PTCLs are not understood. Syk can be phosphorylated through various receptors, including the b-and g-chains of the interleukin-2 receptor and T-cell antigen receptor. 4 Cytokines that signal through receptors sharing the g-chain (for example, interleukin-2) may contribute to PTCL growth, but the extent to which such signaling is Sykdependent is unclear. Both SU-DHL-1 and SR-786 are cell lines derived from anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphomas (ALCLs). The specific effects of ALK on Syk expression and activation are unknown, but warrant further study as SYK upregulation has been reported in ALK-positive ALCLs. 5 Conversely, the extent to which Syk may contribute to lymphomagenesis in ALK-negative PTCLs, including PTCL unspecified, will require further study, ideally using primary tumor samples. Although 'tonic' B-cell receptor signaling in diffuse large B-cell lymphomas may be Sykdependent, 1 an analogous role for T-cell antigen receptor signaling in PTCLs has not been described. In fact, PTCLs often lack an intact T-cell antigen receptor-signaling apparatus, as we observed in both SU-DHL-1 and SR-786 cells (data not shown). In B-cell lymphomas, Syk phosphorylation also is regulated by protein tyrosine phosphatases (PTPs), 6 and diminished PTP expression may contribute to Syk activity. As diminished PTP expression has been identified in malignant T cells, effects of PTPs on Syk regulation in PTCLs merit further study.
Syk can function through a variety of downstream pathways, including MAPK, PI3K and PLC-g activation. 4 The pathways responsible for the functional effects of Syk in PTCLs are unknown. Furthermore, in addition to promoting cell growth and survival, Syk may have other functional effects in PTCLs; Letters to the Editor for example, Syk regulates tumor cell migration and cytokine production in various solid tumors. 7 Finally, though normal T cells lack Syk expression, recent data indicate that Syk is overexpressed and functionally active in T cells from patients with systemic lupus erythematosis. 8 Syk signaling in these cells occurs through preferential binding to Fc receptor gamma chain (FcR-g), resulting in altered calcium flux and actin polymerization. These findings may offer additional clues to the function of Syk in PTCLs.
In summary, our data provide the first evidence of a functional role for Syk in survival and growth of malignant T cells, and validate Syk as a rational therapeutic target in PTCLs. As PTCL patients currently lack good treatment options, our findings support the novel therapeutic approach of Syk inhibition for these malignancies.
PTPN11 mutations in childhood acute lymphoblastic leukemia occur as a secondary event associated with high hyperdiploidy The protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene encodes SHP-2, a phosphatase involved in many signaling pathways, with a key role in development and hematopoiesis. Somatic PTPN11 mutations were found with variable prevalences in pediatric leukemia, most frequently associated with juvenile myelomonocytic leukemia (JMML).
1,2 In vitro and in vivo studies, mainly in a myeloid context, demonstrated a crucial involvement of PTPN11 mutations in the hyperactivation of the RAS/ERK pathway. 3 The oligoclonality of transgene integration sites, and the long latency before overt leukemia in mice transduced with mutant PTPN11, 3 suggested that additional molecular lesions are needed to cooperate with PTPN11 mutations in leukemogenesis. This observation is in line with the 'two hit model' proposed by Greaves 4 for B-cell precursor childhood acute lymphoblastic leukemia (ALL), in which an initiating alteration, often occurring prenatally, gives rise to a preleukemic clone, which eventually becomes fully malignant by subsequent acquisition of other molecular alterations.
We previously documented that somatically acquired PTPN11 mutations occur in approximately 10% of B-cell precursor childhood ALL. 2 Molecular profiling indicated that PTPN11 mutations were largely mutually exclusive with NRAS and KRAS mutations, suggesting a perturbing role of PTPN11 mutations on signal flow through RAS in ALL as well. In childhood ALL, high hyperdiploidy (450 chromosomes) is the most frequent cytogenetic aberration, accounting for 30% of the cases. 5 Although several lines of evidence support the view that hyperdiploidy is an early leukemogenic event, frequently occurring prenatally, 6 the long latency before overt leukemia strongly indicates that, also for hyperdiploidy, additional alterations in the leukemic clone are required. 6 Although a higher prevalence of mutations in genes coding for transducers with a role in RAS signaling in high hyperdiploid childhood ALL cases has been reported, 7, 8 the order of the events before overt disease in PTPN11-mutated ALL has not been addressed.
With this aim, we genotyped the available DNA from relapsed ALL cases with a PTPN11 mutation at disease presentation, and performed single-nucleotide polymorphism (SNP) mapping analysis in PTPN11-mutated cases at diagnosis to identify the presence of additional genetic alterations.
In our previous screening, we identified 23 PTPN11 mutationpositive ALL patients. 2 Among these cases, four patients relapsed, and biological samples of three patients were available to be genotipically characterized (Figure 1 ). All patients studied were enrolled in the AIEOP-BFM ALL 2000 clinical trial, approved
